Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Complementary ideas

    C4 levels drive schizophrenia risk

    A link between complement and schizophrenia raises new possibilities for treatment and a debate about pruning.

    Published on 2/11/2016
  • Figure: Structured risk

    Complementary ideas Targets & Mechanisms Structured risk A Harvard group has traced one of the strongest genetic risk factors for schizophrenia to the C4 gene. The team showed structural variation in C4 controls …

    Published on 2/11/2016
  • PPP tipping point

    BioCentury's annual look shows PPPs on the backslide

    BioCentury's annual roundup suggests the trend towards public-private partnerships may have peaked.

    Published on 2/4/2016
  • Figure: Continental Differences

    PPP tipping point Finance Continental Differences While U.S.-based companies and institutions continued to put faith in public-private partnerships (PPPs) in 2015 as a vehicle for advancing research, with almost as…

    Published on 2/4/2016
  • Figure: Declining consortia

    PPP tipping point Finance Declining consortia The number of new consortium-oriented public-private partnerships (PPPs) formed in 2015 decreased from 2014, suggesting a declining trend in multilateral and complex …

    Published on 2/4/2016
  • Figure: PPP slow slide

    PPP tipping point Finance PPP slow slide The total number of public-private partnerships (PPPs) worldwide disclosed in 2015 continued a tailing off in creation of new collaborations between academia and industry …

    Published on 2/4/2016
  • Figure: Regional Tides

    PPP tipping point Finance Regional Tides California continued to play a leading role in the formation of public-private partnerships (PPPs), while the emerging biotech hub in New York led in the U.S. in terms of …

    Published on 2/4/2016
  • Figure: Top Dealers

    PPP tipping point Finance Top Dealers Leading institutes and companies in formation of public-private partnerships (PPPs) in 2015 compared with 2014. The three leading companies and two of the leading institutes …

    Published on 2/4/2016
  • Figure: Don't grow up too fast

    Peer pressure Tools & Techniques Don't grow up too fast In a Journal of Clinical Investigation study, researchers from the National Cancer Institute (NCI) showed co-culture of naïve (light blue) and memory (dark …

    Published on 1/28/2016
  • Table: BioCentury Product Profile

    Peer pressure Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Naïve T cells for adoptive immunotherapy Inhibitors of FASL signaling:(a) An anti-FASL mAb(b) A …

    Published on 1/28/2016
  • Peer pressure

    Shielding naïve T cells from older cells could improve adoptive immunotherapy

    Blocking "corrupting" signals between mature and naïve T cells during in vitro culture could improve the efficacy of adoptive immunotherapy.

    Published on 1/28/2016
  • Box: Getting to the stem of DMD

    Snipping vs. skipping for DMD Targets & Mechanisms Getting to the stem of DMD Skeletal muscle stem cells - also known as satellite cells - have been largely overlooked in treatment of Duchenne muscular dystrophy (…

    Published on 1/21/2016
  • Figure: Exon skipping vs. CRISPR

    Snipping vs. skipping for DMD Targets & Mechanisms Exon skipping vs. CRISPR With the efficacy of antisense and small molecule therapeutics that bypass disease-causing mutations in Duchenne muscular dystrophy (DMD) …

    Published on 1/21/2016
  • Snipping vs. skipping for DMD

    Why CRISPR might be better than exon skipping for DMD

    Three studies show gene editing in DMD can improve muscle function in mice, but this week's setbacks for the late-stage exon-skipping compounds may have raised the bar for efficiency.

    Published on 1/21/2016
  • Moot point in AD

    A master regulator means there's no need to pick a side in β-amyloid vs. tau

    A new target upstream of β-amyloid and tau could get around the need to pick one pathway over the other.

    Published on 1/14/2016
  • Figure: One inhibitor, two pathways

    Moot point in AD Targets & Mechanisms One inhibitor, two pathways Two studies from an Emory University team showed AEP sits atop both the tau and β-amyloid pathways in Alzheimer's disease (AD) and suggest …

    Published on 1/14/2016
  • Figure: Whither AEP?

    Moot point in AD Targets & Mechanisms Whither AEP? In separate papers in Nature Medicine and Nature Communications, a group at Emory University showed the protease AEP contributes to cognitive deficits in Alzheimer…

    Published on 1/14/2016
  • Table: Biocentury Product Profile

    Moot point in AD Targets & Mechanisms Biocentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product AEP inhibitor Concept A treatment for Alzheimer's disease that suppresses both the β-amyloid…

    Published on 1/14/2016
  • State of the NIH

    NIH Director Francis Collins outlines agency strategy with five-year plan

    NIH Director Francis Collins believes the five-year strategic plan requested by Congress is a chance for the agency to woo the public.

    Published on 1/7/2016
  • A meeting about a meeting

    International gene editing summit kicks can down the road

    The international summit on gene editing was enough of a kumbaya for organizers to declare success, but postponed hard decisions for another day.

    Published on 12/17/2015
  • Spark in the brain

    How Spark is expanding its gene therapy focus to rare neurological disorders

    Spark Therapeutics is using a gene therapy platform for Batten disease that could be leveraged across other neurodegenerative disorders.

    Published on 12/10/2015
  • Box: Evotec battles Batten

    Spark in the brain Product R&D Evotec battles Batten In October, Evotec AG and the Beyond Batten Disease Foundation (BBDF) launched a partnership to identify drug candidates for juvenile Batten disease based on …

    Published on 12/10/2015
  • Figure: Ependymal delivery

    Spark in the brain Product R&D Ependymal delivery Previous attempts to deliver gene therapy to the CNS have involved direct injection into the brain parenchyma, but that approach limits the distribution of the …

    Published on 12/10/2015
  • Microbiome at the checkpoint

    CTLA-4 and PD-L1 blockade depends on specific commensal bacteria

    A pair of studies links the microbiome directly with the activity of checkpoint inhibitors and has triggered new academic partnerships for Enterome Bioscience and Evelo Therapeutics.

    Published on 12/3/2015
  • Table: Tracking competition

    Bell's magnetic organelles Tools & Techniques Tracking competition Bell Biosystems Inc. is developing Magnelle MRI contrast agents, a new class of imaging agents optimized for tracking cell therapies in animals and…

    Published on 11/19/2015

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993